Hologic Offloads LIFECODES Biz - Analyst Blog
25 3월 2013 - 11:30PM
Zacks
Recently, Hologic
Inc. (HOLX) completed the divestment of its LIFECODES
business unit to Immucor Inc., a prominent player in the automated
instrument–reagent systems space in the blood transfusion
industry.
Earlier, on Jan 3, Hologic had announced its definitive agreement
to sell its LIFECODES business in order to focus on its core
business activities. As expected, Hologic successfully completed
the divestiture in the second quarter of fiscal 2013.
Per the agreement, Hologic received cash payment of $85 million
(adjusted for working capital items). The company might also
receive a contingent payment of $10 million from Immucor depending
on the fulfillment of certain financial goals for the ongoing
year.
LIFECODES became a part of Hologic’s broad based business after the
Gen-Probe acquisition in Aug 2012. The business unit comprises the
transplant diagnostic division under the company’s mainstay
Diagnostic segment.
The divestment of LIFECODES will enable Hologic to sharpen its
focus on other operating platforms under its Diagnostic segment,
which are more in tune with its current growth strategy. The sale
will allow it to direct resources towards core operations in order
to leverage top-line.
In fiscal 2012, Hologic’s long-term debt (net of current portion)
increased more than two fold to almost $5 billion. With a
debt-to-capital ratio of approximately 63% in fiscal 2012, the
balance sheet appears to be highly leveraged.
Although the divestment will garner incremental funds for the
company and reduce its debt, we are wary about Hologic’s ability to
improve its debt position immediately on the heels of the LIFECODES
divestment.
Offering a wide range of products, Hologic is an industry leader in
the field of women’s health. While the company continues to deliver
robust top-line growth, its bottom-line remains under continuous
pressure due to higher interest expense from a huge debt burden due
to the Gen-Probe acquisition and pipeline development.
The stock carries a Zacks Rank #3 (Hold). Although we remain on the
sidelines for Hologic, we believe that other medical stocks such as
Abaxis (ABAX), Conceptus (CPTS)
and Cyberonics (CYBX) are likely to do well. These
stocks carry a Zacks Rank #2 (Buy) each.
ABAXIS INC (ABAX): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Abaxis, Inc. (delisted) (나스닥)의 실시간 뉴스: 최근 기사 0
More Abaxis, Inc. (MM) News Articles